The India CDMO market size reached USD 7.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 15.4 Billion by 2033, exhibiting a growth rate (CAGR) of 7.7% during 2025-2033. The market is experiencing robust growth, principally influenced by the increasing demand for contract manufacturing services in pharmaceuticals, particularly for complex generics, HPAPIs, and sterile injectables. With a strong regulatory framework and associated cost advantages, Indian CDMOs are expanding their global footprint, catering to markets like the U.S., Europe, and emerging economies, thereby creating a positive market outlook.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024 |
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 7.9 Billion |
Market Forecast in 2033 | USD 15.4 Billion |
Market Growth Rate 2025-2033 | 7.7% |
Expansion of Biologics and Biosimilars Manufacturing
The contract development and manufacturing organization (CDMO) market in India is witnessing strong growth due to the rising demand for biologics and biosimilars. As global pharmaceutical companies increasingly outsource biologic drug development and production, Indian CDMOs are investing in advanced biomanufacturing capabilities, including mammalian and microbial expression systems. The push for affordable biosimilars is driving partnerships between firms, positioning India as a key hub for cost-effective, high-quality biologics production. For instance, in December 2024, Mankind Pharma Ltd announced a strategic partnership with Innovent Biologics to license and commercialize Sintilimab in India, aiming to improve cancer treatment access by providing innovative immunotherapy solutions to address critical healthcare challenges in the region. Additionally, the expansion of state-of-the-art bioreactors, single-use technologies, and process optimization strategies is enhancing efficiency and scalability in biopharmaceutical manufacturing. Regulatory alignment with agencies like USFDA and EMA further strengthens India’s competitive advantage in contract manufacturing. As the demand for targeted therapies, monoclonal antibodies, and gene-based treatments rises, Indian CDMOs are expected to play a critical role in supplying global markets, ensuring cost efficiency while maintaining high regulatory and quality standards.
Increasing Demand for End-to-End CDMO Services
Pharmaceutical companies are increasingly seeking end-to-end services from CDMOs, covering drug discovery, formulation development, clinical trial support, commercial-scale production, and regulatory compliance. This trend is driven by the need for faster time-to-market, cost-efficiency, and streamlined supply chains. Indian CDMOs are expanding their capabilities to offer comprehensive solutions, enabling global drug developers to outsource the entire product lifecycle under a single contract. The integration of AI-driven drug discovery, process automation, and real-time data analytics is further enhancing efficiency in development and manufacturing. Additionally, CDMOs are focusing on high-potency active pharmaceutical ingredients (HPAPIs), complex generics, and sterile injectables, strengthening their position as strategic outsourcing partners. For instance, in January 2024, Aragen Life Sciences announced a substantial investment of INR 20 Billion (approximately US$230.5 Million) in Telangana to bolster its drug discovery, development, and manufacturing capabilities, reflecting a strategic focus on expanding complex generics and HPAPI production. In addition, government incentives for pharmaceutical innovation, regulatory harmonization, and infrastructure development are supporting this growth. With increasing investments in R&D facilities, analytical services, and quality control, Indian CDMOs are emerging as preferred partners for global pharmaceutical companies seeking cost-effective, high-quality solutions.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the region level for 2025-2033. Our report has categorized the market based on service type, type, scale of operation, and therapeutic area.
Service Type Insights:
The report has provided a detailed breakup and analysis of the market based on the service type. This includes contract development services (preclinical development, clinical development, and analytical and bioanalytical services) and contract manufacturing services (active pharmaceutical ingredients (APIs) manufacturing, finished dosage forms (FDFs) manufacturing, biologics manufacturing, and packaging).
Type Insights:
A detailed breakup and analysis of the market based on the type have also been provided in the report. This includes small molecules, biologics, biosimilars, vaccines, and others.
Scale of Operation Insights:
The report has provided a detailed breakup and analysis of the market based on the scale of operation. This includes commercial scale and clinical scale.
Therapeutic Area Insights:
A detailed breakup and analysis of the market based on the therapeutic area have also been provided in the report. This includes oncology, cardiovascular diseases, infectious diseases, central nervous system (CNS) disorders, and others.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include North India, South India, East India, and West India.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Scope of the Report | Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Service Types Covered |
|
Types Covered | Small Molecules, Biologics, Biosimilars, Vaccines, Others |
Scale of Operations Covered | Commercial Scale, Clinical Scale |
Therapeutic Areas Covered | Oncology, Cardiovascular Diseases, Infectious Diseases, Central Nervous System (CNS) Disorders, Others |
Regions Covered | North India, South India, East India, West India |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
Key Benefits for Stakeholders: